JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
Yohimbine represents a significant research tool for investigating alpha-2 adrenergic receptor pharmacology and mitochondrial pathway modulation in cell-based experimental systems. This indole alkaloid compound demonstrates selective alpha-2 adrenergic receptor (alpha-2 AR) competitive antagonism, resulting in cAMP disinhibition through specific molecular mechanisms. Published in vitro research extensively characterizes its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions.
The compound's research applications span multiple cellular pathway investigations, including adrenergic signalling cascades, mitochondrial bioenergetics, and cyclic nucleotide-mediated responses. Laboratory studies utilizing various cell lines and tissue preparations have established yohimbine's receptor selectivity profiles and concentration-dependent effects across diverse experimental protocols.
Yohimbine functions as a selective alpha-2 adrenergic receptor competitive antagonist, demonstrating high binding affinity for alpha-2A, alpha-2B, and alpha-2C receptor subtypes. In vitro binding studies reveal Ki values ranging from 1-10 nM across these receptor subtypes, indicating potent receptor interaction capabilities. The compound exhibits competitive inhibition kinetics, displacing endogenous ligands and synthetic agonists in radioligand binding assays.
Cell-based expression systems utilizing recombinant alpha-2 AR subtypes demonstrate yohimbine's ability to block receptor activation by norepinephrine, epinephrine, and selective alpha-2 agonists. Functional antagonism studies in CHO cells and HEK293 cells expressing specific alpha-2 receptor subtypes confirm the compound's competitive nature, with rightward shifts in agonist concentration-response curves proportional to yohimbine concentrations.
Research investigations reveal yohimbine's selectivity for alpha-2 ARs over alpha-1 adrenergic receptors, with approximately 40-fold selectivity for alpha-2 versus alpha-1 receptor subtypes. This selectivity profile enables specific modulation of alpha-2-mediated signalling pathways without significant interference from alpha-1 receptor systems in experimental protocols.
Additional receptor screening studies demonstrate minimal interaction with beta-adrenergic receptors, dopamine receptors, and serotonin receptor subtypes at concentrations used for alpha-2 AR research applications.
Alpha-2 adrenergic receptors couple to Gi/Go proteins, resulting in adenylyl cyclase inhibition and reduced cyclic adenosine monophosphate (cAMP) formation. Yohimbine's antagonist activity at alpha-2 ARs prevents this inhibitory modulation, leading to disinhibition of adenylyl cyclase activity and subsequent cAMP elevation in responsive cell systems.
In vitro cAMP accumulation assays utilizing forskolin stimulation demonstrate yohimbine's ability to enhance cAMP formation in cells expressing functional alpha-2 ARs. Time-course studies reveal rapid onset of cAMP disinhibition following yohimbine administration, with peak effects observed within 5-15 minutes in most cell model systems.
Elevated cAMP concentrations resulting from yohimbine-induced alpha-2 AR antagonism activate protein kinase A (PKA) signalling cascades. PKA activation leads to phosphorylation of multiple downstream targets, including transcription factors, metabolic enzymes, and regulatory proteins involved in cellular energy metabolism.
Research utilizing specific PKA activity assays demonstrates concentration-dependent PKA activation following yohimbine treatment in appropriate cell culture systems. These effects correlate directly with cAMP elevation patterns and alpha-2 AR expression levels across different cell lines.
Yohimbine's effects on cellular energy metabolism extend to mitochondrial function modulation through indirect mechanisms involving adrenergic pathway activation. Research investigations utilizing isolated mitochondrial preparations and intact cell respirometry reveal complex interactions between yohimbine-mediated pathway activation and mitochondrial respiratory chain function.
Cell culture studies employing oxygen consumption measurements demonstrate altered mitochondrial respiration patterns following yohimbine treatment, particularly in cell lines expressing high levels of alpha-2 adrenergic receptors. These effects appear mediated through PKA-dependent phosphorylation events affecting key mitochondrial regulatory proteins.
Laboratory investigations utilizing metabolic flux analysis reveal yohimbine's influence on cellular oxidative metabolism through alpha-2 AR-mediated pathway modulation. These studies demonstrate altered substrate utilization patterns and respiratory quotient measurements in responsive cell systems.
Yohimbine serves as a valuable pharmacological tool for investigating alpha-2 adrenergic receptor function and associated cellular signalling pathways in vitro research applications. Its selective competitive antagonism at alpha-2 ARs enables precise modulation of cAMP-mediated signalling cascades and downstream protein kinase A activation. The compound's well-characterized receptor binding profile and cellular effects make it suitable for mechanistic studies involving adrenergic pathway function, mitochondrial bioenergetics, and cyclic nucleotide signalling systems in controlled laboratory environments.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
